Conference Cochairs:
Dan Theodorescu, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, CA
Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, TX
Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
Lars Dyrskjøt, Department of Molecular Medicine, Aarhus University Hospital, Denmark

FRIDAY, MAY 17

Registration
4:00 pm-8:00 pm | Carolina Foyer

Welcome and Introduction
6:30 pm-6:40 pm | Carolina AC
Not-CME eligible

Opening Keynote Address
6:40 pm-7:30 pm | Carolina AC
CME eligible

6:40- 6:45 p.m.  Introduction of Keynote Speaker
Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, CA

6:45- 7:30 p.m.  Cellular and molecular underpinnings of field cancerization and progression to invasive carcinoma in bladder cancer
Philip A. Beachy, Stanford University, Stanford, CA

Opening Reception
7:30 pm-9:00 pm | Symphony I
SATURDAY, MAY 18

Continental Breakfast
7:00 am-8:00 am | Mecklenberg

Plenary Session 1: Tumor subtypes in 2024 and beyond – biological framework and potential clinical impact
8:00 am-9:30 am | Carolina AC
Session Chair and Moderator: Lars Dyrskjøt (Aarhus University)
CME eligible

8:00-8:20 p.m. Dare to be different - understanding subtypes and divergence in urothelial carcinoma
Sara E. Wobker, University of North Carolina Chapel Hill, Charlotte, NC

8:20-8:40 p.m. Molecular subtypes of NMIBC
Sia V. Lindskrog, Aarhus University Hospital, Aarhus, Denmark

8:40-9:00 p.m. Molecular subtypes and clinical benefit from neoadjuvant chemotherapy: A ten-year update
David J. McConkey, Johns Hopkins University, Baltimore, MD

9:00-9:30 p.m. Panel Discussion: Drs. Dyrskjøt, Lindskrog, Wobker and McConkey

Break
9:30 am-10:00 am | Carolina Foyer

Plenary Session 2: Liquid biopsies for guiding treatment decisions
10:00 am-11:30 am | Carolina AC
Session Chair: Philip Abbosh (Fox Chase)
CME eligible

10:00-10:30 am Urine based liquid biopsy for the diagnosis, assessment, and staging of bladder cancer
Philip H. Abbosh, Fox Chase Cancer Center, Philadelphia, PA

10:30-11:00 am Circulating biomarkers in bladder cancer: can we predict relapse
Peter Kuhn, University of Southern California, Los Angeles, California

11:00-11:30 am Towards ctDNA-guided treatment of muscle-invasive bladder cancer
Lars Dyrskjøt, Aarhus University Hospital, Aarhus, Denmark
Lunch on own
11:30 pm-1:30 pm

Plenary Session 3: Sex, Hormone and stromal interactions in tumor growth and progression
1:30 pm-3:00 pm | Carolina AC
Session Chair: Zihai Li (Ohio State)
CME eligible

1:30 -2:00 pm  Sex-based disparities in urothelial carcinoma: pathology and diagnosis
Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, TX

2:00 -2:30 pm  Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, CA

2:30 -3:00 pm  Immunological basis of sex bias and therapeutic opportunities in bladder cancer
Zihai Li, Ohio State University, Columbus, OH

Break
3:00 pm-3:15 pm | Carolina Foyer

Proffered Talks *
Session Chair: Donna Hansel (MD Anderson)
3:15 pm-4:00 pm | Carolina AC
CME eligible

3:15 -3:30 pm  Exploring the functional consequences of APOBEC3-induced non-coding hotspot mutations in bladder cancer using massively parallel reporter assays and CRISPR-mediated base editing.*
Rouf Banday, National Cancer Institute, Rockville, MD

3:30 -3:45 pm  TRIM29 is required for basal bladder cancer invasive progression*
Alan Kelleher, University of Michigan, Ann Arbor, MI

3:45 -4:00 pm  Sarcomatoid histological variants of canine muscle-invasive bladder cancer: transcription factor activation highlights pathways of epithelial-mesenchymal transformation similar to humans*
Karin Allenspach, University of Georgia, Athens, GA
Lightning talks Session I
Session Chair: Donna Hansel (MD Anderson)
4:00 pm-4:15 pm | Carolina AC

4:05 -4:07 pm Integrative drug screening and multi-omic characterization of patient-derived bladder cancer organoids reveals novel molecular correlates of chemotherapy response
Nathan Merrill, University of Michigan, Ann Arbor, MI

4:09 -4:11 pm Racial differences in characteristics and outcomes of adjuvant nivolumab for muscle-invasive urothelial carcinoma (MIUC) in the real-world setting
Regina Barragan-Carrillo, City of Hope Comprehensive Cancer Center, Duarte, CA

Poster Session A / Reception
4:15 pm-6:15 pm | Mecklenberg
Not-CME eligible

SUNDAY, MAY 19

Continental Breakfast
7:00 am-8:00 am | Mecklenberg

Plenary Session 4: Immune cell context and treatment responses
8:00 am-10:00 am | Carolina AC
Session Chair: Dan Theodorescu (Ceders-Sinai)
CME eligible

8:00 -8:30 am Tumor HLA-E expression and cytomegalovirus infection modulate NK cell activity in human bladder cancer
Amir Horowitz, Icahn School of Medicine at Mount Sinai, New York, NY

8:30 -8:45 am Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment*
Trine Strandgaard, Aarhus University Hospital, Arhus, Denmark
8:45 -9:15 am  Dissecting innate immune mechanisms of resistance to immune checkpoint blockade therapy in bladder cancer [R]
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY

9:15 -9:30 am  T cell receptor repertoire and diversity are prognostic markers in bladder cancer*
Nanna Kristjánssdóttir, Aarhus University, Arhaus, Denmark

9:30 -10:00 am  Immune cell context in BCG-treated patients
Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Break
10:00 am-10:30 am | Carolina Foyer

Plenary Session 5: Novel approaches for managing non-invasive disease
10:30 am-12:30 pm | Carolina AC
Session Chair: Ashish Kamat (MD Anderson)
CME eligible

10:30 -11:00 am  Setting the stage for trials in NMIBC
Ashish M. Kamat, The University of Texas MD Anderson Cancer Center, Houston, TX

11:00 -11:15 am  EG-70 (detalimogene voraplastmid), a novel, non-viral intravesical gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: preclinical characterization and translation into the clinic*
James Sullivan, enGene Inc, Boston, MA

11:15 -11:45 am  Conditional reprogramming modeling of bladder cancer for clinical translation
Cheryl T. Lee, The Ohio State University, Columbus, OH

11:45 -12:00 pm  Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer*
Syed Alam, Memorial Sloan Kettering Cancer Center, New York, NY

12:00 -12:30 pm  The evolution of multi-disciplinary care for non-muscle invasive bladder cancer patients
Noah M. Hahn, Johns Hopkins University, Baltimore, MD
Lunch on Own  
12:30 pm-2:00 pm

Plenary Session 6: Novel approaches for managing invasive disease  
2:00 pm-4:00 pm | Carolina AC  
*Session Chair: Tahlita Zuiverloon*  
*CME eligible*

2:00 -2:30 pm  
**Current state of the art: Bladder-preserving trimodality therapy for muscle-invasive bladder cancer**  
Jason A. Efstathiou, Massachusetts General Hospital, Boston, MA

2:30 -2:45 pm  
**Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy***  
Jonathan Chou, University of California San Francisco, San Francisco, CA

2:45 -3:15 pm  
**Defining the actionable genome**  
David B. Solit, Memorial Sloan Kettering Cancer Center, New York, NY

3:15 -3:45 pm  
**Optimizing cystectomy outcomes in MIBC: What’s new in 2024?**  
Jeremy Teoh, The Chinese University of Hong Kong, Hong Kong

3:45 -4:00 pm  
**Identifying targeted therapies for muscle invasive bladder cancer via STAG2 expression***  
Sarah Athans, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Lightning Talk Session II  
4:00 pm-4:05 pm | Carolina AC  
*Session Chair: Tahlita Zuiverloon*  
*CME eligible*

4:03 -4:05 pm  
**Novel mesothelin-based CAR T cells targeting MUC16 as an intravesical bladder cancer therapy**  
Parwiz Abrahimi, Weil Cornell Medicine, New York, NY

Poster Session B/ Reception  
4:15 pm-6:15 pm | Mecklenberg  
*Not-CME eligible*
MONDAY, MAY 20

Continental Breakfast
7:00 am-8:00 am | Mecklenberg

Plenary Session 7: Management and treatment of metastatic disease
8:00 am-9:30 am | Carolina AC
Session Chair: Nicholas Simon (NCI)
CME eligible

8:00 -8:30 am The evolving role of immune-based treatment strategies in metastatic urothelial cancer
Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, NY

8:30 -9:00 am The interplay between mutagenesis and extrachromosomal DNA shapes urothelial cancer evolution
Bishoy M. Faltas, Weill Cornell Medicine, New York, NY

9:00 -9:30 am Metastatic bladder cancer: The expanding role of antibody drug conjugates
Nicholas Simon, National Institutes of Health, Bethesda, MD

Break
9:30-9:45 am | Carolina Foyer

Closing Keynote Address
9:45 am-10:30 am | Carolina AC
CME eligible

9:45 -9:47 am Introduction of Keynote Speaker
Lars Dyrskjøt, Aarhus University Hospital, Denmark
Not-CME eligible

9:47 -10:30 am Lessons from glioblastoma diversity, heterogeneity, and beginnings
Luis F. Parada, Memorial Sloan Kettering Cancer Center, New York, New York
Plenary Session 8: Future of Artificial Intelligence in bladder cancer research and patient management
10:30 am-12:30 pm | Carolina AC
Session Chair: Joshua J. Levy (Cedars-Sinai)
CME eligible

10:30 -11:00 am  
Al-powered tool for rapid reliable bladder cancer screening and surveillance: multicenter validation efforts  
Joshua J. Levy, Cedars Sinai Medical Center, Los Angeles, CA

11:00 -11:15 am  
Exploratory analysis of tumor tertiary lymphoid structures using a novel artificial intelligence–based approach in patients with muscle-invasive urothelial carcinoma from the CheckMate 274 trial*  
Matthew Milowsky, University of North Carolina at Chapel Hill, Chapel Hill, NC

11:15 -11:15 am  
AI-driven multimodal computational pathology  
Faisal Mahmood, Harvard Medical School, Boston, MA

11:45 -12:00 pm  
Imaging mass cytometry captures patient heterogeneity enabling BCG response stratification in non-muscle invasive bladder cancer*  
Ali Foroughi Pour, The Jackson Laboratory for Genomic Medicine, Farmington, CT

12:00 -12:30 pm  
AI in bladder cancer pathology and research: What can we expect and what not?  
Markus Eckstein, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Closing Remarks | Carolina AC
12:30 p.m.